The chief executive of the biotechnology group behind the first Covid-19 vaccine has said a new formulation is likely to be needed by the middle of next year to protect against the virus as it mutates.
Ugur Sahin, chief executive of BioNTech, told the Financial Times that as time passes, mutations will emerge that can evade the body’s immune defences. “This year [a different vaccine] is completely unneeded. But by mid next year, it could be a different situation,” he predicted.
A partnership between the German biotech and US pharmaceutical company Pfizer brought the first Covid-19 vaccine to market. It was also the first vaccine based on mRNA technology to win regulatory approval, and has been the world’s best-selling drug this year.
How bout kick them out and welcome Novavax and Clover Vax?
sounds like forecast of new iPhone release.
(04-10-2021, 01:39 PM)lvlrsSTI Wrote: [ -> ]sounds like forecast of new iPhone release.
This year iphone emphasizes on camera features how good they are but they did not notice one of the China Handphone maker, the camera features are much better than Iphone pro?
